Please note that any funds granted from the FSHD Canada Foundation cannot be used to cover more than ten percent (10%) of overhead costs.
Working Towards an ASO Treatment for FSHD2 Patients
Investigator: Dr. Stanley Crooke FSHD is a rare disease. FSHD2 is even more rare. Only 5% of all FSHD patients have FSHD2. We don’t want them to get left behind. The…
Read MoreAccelerating Canadian Regulatory Approvals
The Objective Several promising treatments for FSHD are going into clinical trials very soon. Hopefully, these therapies will be approved for use by FSHD patients in the next couple of…
Read MoreDiagnostics
Investigator Takako Jones, PhD (University of Nevada, Reno School of Medicine) Current FSHD diagnostics are complex, expensive, and not widely available. In addition, the disease itself has wide variability in…
Read MoreBiomarkers
Investigators: Yi-Wen Chen (Children’s National Hospital, Washington, DC) Giorgio Tasca & Enzo Ricci (Università Cattolica del Sacro Cuore – Rome) Sabrina Sacconi (Centre Hospitalier Universitaire de Nice) Biomarkers are used…
Read MoreClinical Trial Research Network (CTRN)
Investigators: Jeffrey Statland (University of Kansas Medical Center) and Rabi Tawil (University of Rochester Medical Center) This project includes support for the CTRN to continue the Natural History Studies (MOVE…
Read MoreMuscle targeted immunosuppression as an FSHD therapeutic
Investigator: Andreia Marcelino Nunes, PhD; University of Nevada, Reno School of Medicine FSHD is caused by aberrant increased expression of the DUX4 gene in skeletal myocytes, which initiates a pathogenic…
Read More